Michael C. Roarke, M.D., M.S., studies and treats disease processes using radioisotope-based molecular imaging techniques. Dr. Roarke is active in the evaluation of neurological, cardiovascular and oncologic diseases.
Past research projects included use of C-11 acetate in the imaging of multiple myeloma; use of In-111 capromab in defining appropriate targets for boost-dosing of prostate cancer during radiation therapy; and use of single-photon emission computerized tomography (SPECT) in evaluation of drainage patterns in head and neck lymphoscintigraphy.
- Prostate cancer. Use of C-11 choline in staging of newly diagnosed patients with high-risk prostate cancer. Investigation of new imaging agents that will be part of a theranostic strategy for treating advanced prostate cancer.
- Neurological disease. Use of F-18 FDG PET in the setting of mild cognitive impairment. Subtraction ictal SPECT co-registered to MRI (SISCOM) for refractory epilepsy.
- Oncologic disease. Use of cyclotron-based radiopharmaceuticals in evaluation of primary brain tumors.
Significance to patient care
Dr. Roarke hopes that his research will help advance techniques used to evaluate and treat diseases.